The FDA on April 27, 2017 expanded the indications of STIVARGA® to include the treatment of patients with HepatoCellular Carcinoma (HCC) who have been previously treated with NEXAVAR® (Sorafenib). STIVARGA® is a product of Bayer HealthCare Pharmaceuticals Inc.
Bottom Ad
Advertisement
Subscribe
